![Julius Knowles](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Julius Knowles
Directeur/Membre du Conseil chez
KEROS THERAPEUTICS, INC.
Fortune : 123 278 $ au 31/05/2026
Profil
Julius Knowles is currently an Independent Director at Keros Therapeutics, Inc. since 2016.
Holds Director positions at Abcuro, Inc. and Paros Bio, Inc. Serves as Partner at Mass General Brigham Ventures LLC and Partners Innovation Fund LLC since 2014, and at Partners Innovation Fund II LP.
Formerly Chief Executive Officer at X-Body, Inc. from 2012 to 2014.
Served as Director at Aurigene Oncology Ltd. and Rome Therapeutics, Inc. Was Director-Research & Development Planning at Vertex Pharmaceuticals, Inc. from 1993 to 1999.
Head-Strategic Alliances at Novartis Institutes for Biomedical Research, Inc. from 2006 to 2012.
President of Novalar Pharmaceuticals, Inc. from 2002 to 2006.
Vice President-Business Development at SGX Pharmaceuticals, Inc. from 1999 to 2001 and at Novacea, Inc. from 2001 to 2002.
Education includes an MBA from the University of Pennsylvania in 1993, graduate studies at the University of California, Berkeley in 1987, and an undergraduate degree from Carleton College in 1985.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
KEROS THERAPEUTICS, INC. 0,06 % | 04/06/2026 | 10 958 ( 0,06 % ) | 123 278 $ | 31/05/2026 |
Postes actifs de Julius Knowles
| Sociétés | Poste | Début |
|---|---|---|
| KEROS THERAPEUTICS, INC. | Directeur/Membre du Conseil | 01/04/2016 |
Partners Innovation Fund II LP
 Partners Innovation Fund II LP Investment ManagersFinance Functions as a venture capital fund | Corporate Officer/Principal | - |
Abcuro, Inc.
 Abcuro, Inc. Miscellaneous Commercial ServicesCommercial Services Develops bio therapeutics for treatment of autoimmunity and cancer | Directeur/Membre du Conseil | - |
Partners Innovation Fund LLC
 Partners Innovation Fund LLC Investment ManagersFinance Acts as Venture Capital Fund | Corporate Officer/Principal | 01/01/2014 |
Mass General Brigham Ventures LLC
 Mass General Brigham Ventures LLC Investment ManagersFinance Mass General Brigham Ventures invests in companies located in the United States. The firm targets companies operating in the fields of drugs, devices, diagnostics, and digital health. It provides financing to seed and early stage capital requirements. It also makes co-investments. | Private Equity Investor | 01/01/2014 |
Paros Bio, Inc.
 Paros Bio, Inc. BiotechnologyHealth Technology Engages in developing transformative gene therapies for the treatment of autosomal-dominant Alzheimer's disease | Directeur/Membre du Conseil | - |
Anciens postes connus de Julius Knowles
| Sociétés | Poste | Fin |
|---|---|---|
X-Body, Inc.
 X-Body, Inc. BiotechnologyHealth Technology Provides biotechnological research services | Directeur Général | 01/01/2014 |
Novartis Institutes for Biomedical Research, Inc.
 Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Conducts biomedical researches | Corporate Officer/Principal | 01/02/2012 |
Novalar Pharmaceuticals, Inc.
 Novalar Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures pharmaceutical products | President | 01/06/2006 |
| ░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Julius Knowles
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
80
Relations au 1er degré
17
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 17 |
|---|---|
Vertex Pharmaceuticals, Inc.
 Vertex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops drugs for the treatment of cystic fibrosis | Health Technology |
Novalar Pharmaceuticals, Inc.
Novalar Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures pharmaceutical products | Health Technology |
X-Body, Inc.
X-Body, Inc. BiotechnologyHealth Technology Provides biotechnological research services | Health Technology |
University of Pennsylvania
 University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
SGX Pharmaceuticals, Inc.
 SGX Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Researches and develops drugs and other pharmaceutical products | Health Technology |
Carleton College
 Carleton College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California, Berkeley
 University of California, Berkeley Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Novacea, Inc.
 Novacea, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Novartis Institutes for Biomedical Research, Inc.
Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Conducts biomedical researches | Commercial Services |
Mass General Brigham Ventures LLC
Mass General Brigham Ventures LLC Investment ManagersFinance Mass General Brigham Ventures invests in companies located in the United States. The firm targets companies operating in the fields of drugs, devices, diagnostics, and digital health. It provides financing to seed and early stage capital requirements. It also makes co-investments. | Finance |
Partners Innovation Fund LLC
Partners Innovation Fund LLC Investment ManagersFinance Acts as Venture Capital Fund | Finance |
Aurigene Oncology Ltd.
 Aurigene Oncology Ltd. BiotechnologyHealth Technology Operates as clinical stage biotechnology company | Health Technology |
Keros Therapeutics, Inc.
 Keros Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops therapeutics for muscle diseases | Health Technology |
Partners Innovation Fund II LP
Partners Innovation Fund II LP Investment ManagersFinance Functions as a venture capital fund | Finance |
Abcuro, Inc.
Abcuro, Inc. Miscellaneous Commercial ServicesCommercial Services Develops bio therapeutics for treatment of autoimmunity and cancer | Commercial Services |
Rome Therapeutics, Inc.
 Rome Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops novel therapies for cancer and autoimmune diseases | Health Technology |
Paros Bio, Inc.
Paros Bio, Inc. BiotechnologyHealth Technology Engages in developing transformative gene therapies for the treatment of autosomal-dominant Alzheimer's disease | Health Technology |
